Tizona com­pletes spin­out of can­cer pro­gram as part of Gilead buy­out; Dyne files for $100M IPO

Tizona has com­plet­ed the spin­out of a new com­pa­ny that will fo­cus on de­vel­op­ing its now-for­mer lead pro­gram in­volv­ing an an­ti-CD39 an­ti­body.

The new com­pa­ny, Tr­ishu­la Ther­a­peu­tics, is de­signed to fur­ther progress and fo­cus on the ex­ist­ing TTX-030 col­lab­o­ra­tion that Tizona had signed with Ab­b­Vie back in ear­ly 2019. Cur­rent­ly, the can­di­date is be­ing stud­ied in Phase I/Ib tri­als, both by it­self and in com­bi­na­tion with an an­ti-PD-1 agent and stan­dard chemother­a­py, in adults with ad­vanced can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.